QIAGEN Names Jonathan M. Pratt CEO, Reaffirms 2026 Outlook
QGEN sits 29% above its 52-week low of $32.53.
Summary
QIAGEN appointed Jonathan M. Pratt as CEO effective September 1, 2026, succeeding Thierry Bernard, and reaffirmed its 2026 outlook while the strategic review continues.
Key Events · Executive and Board Changes · QGEN
-
New CEO Appointed
Jonathan M. Pratt named CEO effective September 1, 2026, succeeding Thierry Bernard, who steps down from the Managing Board.
-
CEO Background
Pratt brings 25+ years of life sciences leadership, most recently as CEO of Filtration Group through its August 2026 sale to Parker-Hannifin, and previously at Waters, Beckman Coulter Life Sciences, and Pall.
-
Shareholder Vote Planned
Pratt will be proposed for shareholder approval as Managing Director at an Extraordinary General Meeting planned for Q4 2026.
-
2026 Outlook Reaffirmed
QIAGEN reaffirmed its Q3 and full-year 2026 outlook, citing focus on profitable growth and capital allocation.
Analysis · QGEN · Life Sciences
QIAGEN has appointed Jonathan M. Pratt as CEO effective September 1, 2026, succeeding Thierry Bernard. Pratt brings over 25 years of life sciences leadership experience, most recently as CEO of Filtration Group through its sale to Parker-Hannifin. The company also reaffirmed its Q3 and full-year 2026 outlook and confirmed the strategic review remains ongoing. This leadership change matters because it comes amid reported private equity takeover interest and a recent patent infringement verdict against its Parse Biosciences unit — the new CEO's mandate will likely shape how QIAGEN navigates both the strategic review and the litigation overhang.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QGEN was trading at $42.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $32.53 to $57.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.